中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2014年
2期
126-128
,共3页
周敏%沙信山%仇惠英%何广胜%徐杨%岑建农%潘金兰%陈苏宁%孙爱宁
週敏%沙信山%仇惠英%何廣勝%徐楊%岑建農%潘金蘭%陳囌寧%孫愛寧
주민%사신산%구혜영%하엄성%서양%잠건농%반금란%진소저%손애저
白血病,髓样%伊马替尼%造血干细胞移植%存活率分析
白血病,髓樣%伊馬替尼%造血榦細胞移植%存活率分析
백혈병,수양%이마체니%조혈간세포이식%존활솔분석
Leukemia,myeloid%Imatinib%Hematopoietic stem cell transplantation%Survival
目的 比较伊马替尼与异基因造血干细胞移植(allo-HSCT)治疗慢性髓性白血病(CML)的疗效.方法 回顾性分析292例接受伊马替尼治疗(伊马替尼组)和141例接受allo-HSCT(allo-HSCT组)CML患者的临床资料,分别比较两组慢性期、进展期(加速期和急变期)患者的无事件生存(EFS)率和总体生存(OS)率.结果 伊马替尼组慢性期CML患者(278例)的EFS率、OS率、预期5年EFS率、预期5年OS率均优于allo-HSCT组(120例)(88.5％对70.0％、93.2％对80.0％、84.0％对75.0％、92.0％对79.0％,P值均＜0.01).伊马替尼组进展期CML患者(14例)的EFS率、OS率与allo-HSCT组(21例)比较,差异均无统计学意义(42.9％对47.6％,P=0.688；42.9％对57.1％,P=0.437).结论 伊马替尼治疗慢性期CML患者的EFS及OS率均优于allo-HSCT；对于加速或急变期患者,伊马替尼与 allo-HSCT疗效相当.
目的 比較伊馬替尼與異基因造血榦細胞移植(allo-HSCT)治療慢性髓性白血病(CML)的療效.方法 迴顧性分析292例接受伊馬替尼治療(伊馬替尼組)和141例接受allo-HSCT(allo-HSCT組)CML患者的臨床資料,分彆比較兩組慢性期、進展期(加速期和急變期)患者的無事件生存(EFS)率和總體生存(OS)率.結果 伊馬替尼組慢性期CML患者(278例)的EFS率、OS率、預期5年EFS率、預期5年OS率均優于allo-HSCT組(120例)(88.5％對70.0％、93.2％對80.0％、84.0％對75.0％、92.0％對79.0％,P值均＜0.01).伊馬替尼組進展期CML患者(14例)的EFS率、OS率與allo-HSCT組(21例)比較,差異均無統計學意義(42.9％對47.6％,P=0.688；42.9％對57.1％,P=0.437).結論 伊馬替尼治療慢性期CML患者的EFS及OS率均優于allo-HSCT；對于加速或急變期患者,伊馬替尼與 allo-HSCT療效相噹.
목적 비교이마체니여이기인조혈간세포이식(allo-HSCT)치료만성수성백혈병(CML)적료효.방법 회고성분석292례접수이마체니치료(이마체니조)화141례접수allo-HSCT(allo-HSCT조)CML환자적림상자료,분별비교량조만성기、진전기(가속기화급변기)환자적무사건생존(EFS)솔화총체생존(OS)솔.결과 이마체니조만성기CML환자(278례)적EFS솔、OS솔、예기5년EFS솔、예기5년OS솔균우우allo-HSCT조(120례)(88.5％대70.0％、93.2％대80.0％、84.0％대75.0％、92.0％대79.0％,P치균＜0.01).이마체니조진전기CML환자(14례)적EFS솔、OS솔여allo-HSCT조(21례)비교,차이균무통계학의의(42.9％대47.6％,P=0.688；42.9％대57.1％,P=0.437).결론 이마체니치료만성기CML환자적EFS급OS솔균우우allo-HSCT；대우가속혹급변기환자,이마체니여 allo-HSCT료효상당.
Objective To compare the curative effect of imatinib and allogeneic hematopoietic stem cell transplant (allo-HSCT) in the treatment of chronic myeloid leukemia (CML).Methods 292 CML patients received imatinib,and 141 patients underwent allo-HSCT.The clinical data of these patients were retrospectively analyzed to compare event-free survival (EFS) and overall survival (OS) between these two groups of paients in chronic and advanced (including accelerate and blast)phases.Results ① EFS,OS,expected 5-year EFS and OS of imatinib group (278 patients in chronic phase) were all statistically higher than of allo-HSCT group (120 patients in chronic phase) (88.5％ vs 70.0％,93.2％ vs 80.0％,84.0％ vs 75.0％ and 92.0％ vs 79.0％,respectively,all P values ＜ 0.01).②EFS and OS of imatinib group (14 patients in accelerate and blast phases) were 42.9％ and 42.9％,respectively.Meanwhile EFS and OS of allo-HSCT group (21 patients in accelerate and blast phases) were 47.6％ and 57.1％,respectively.There were no significant differences in terms of EFS and OS between the two groups (P values ＞0.05).Conclusions EFS and OS of imatinib group were significantly higher than of allo-HSCT group for CML patients of in chronic phase.Imatinib and allo-HSCT had the similar efficacy for CML patients in accelerate and blast phases.
